Alfred marshall lecture intellectual property rights protection in developing countries: The case of pharmaceuticals

Journal of the European Economic Association

Volumn 8, Issue 2-3, 2010, Pages 326-353

  Goldberg, Pinelopi Koujianou ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950993103     PISSN: 15424766     EISSN: 15424774     Source Type: Journal    
DOI: 10.1111/j.1542-4774.2010.tb00506.x     Document Type: Article

References (32)

1. Arora, Ashish, Lee Branstetter, and Chirantan Chatterjee (2008). "Strong Medicine? Patent Reform and the Transformation of the Indian Pharmaceutical Industry." Working paper, Carnegie Mellon University.
2. Berndt, Ernst (1994). Uniform Pharmaceutical Pricing: An Economic Analysis. AIE Press, American Enterprise Institute for Public Policy Research.
3. Challu, Pablo (1991). "The Consequences of Pharmaceutical Product Patenting." World Competition, 15(2), 65-126.
4. Chaudhuri, Shubham, Pinelopi Goldberg, and Panle Jia (2006). "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India." American Economic Review, 96(5), 1477-1513.
5. Chin, Judith, and Gene Grossman (1990). "Intellectual Property Rights and North-South Trade. " In The Political Economy of International Trade: Essays in Honor of Robert E. Baldwin, edited by Ronald W. Jones and Anne O. Krueger. Basil Blackwell.
6. Danzon, Patricia, and Andrew Epstein (2008). "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets." National Bureau of Economic Research Working Paper No. 14041.
7. Danzon, Patricia, Y. Richard Wang, and Liang Wang (2005). "The Impact of Price Reg- ulation on the Launch Delay of New Drugs. " Journal of Health Economics, 14, 269-292.
8. Deardoff, Alan (1992). "Welfare Effects of Global Patent Protection. " Economica, 59, 35-51.
9. Deaton, Angus, and John Muellbauer (1980a). "An Almost Ideal Demand System." American Economic Review, 70, 312-326.
10. Deaton, Angus, and John Muellbauer (1980b). EconomicsandConsumerBehavior. Cambridge University Press.
11. Diwan, Ishac, and Dani Rodrik (1991). "Patents, Appropriate Technology, and North-South Trade." Journal of International Economics, 63, 79-90.
12. Ellison, Sara Fisher, Iain Cockburn, Zvi Griliches, and Jerry Hausman (1997). "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins." RAND Journal of Economics, 28, 426-446.
13. Fink, Carsten (2000). "How Stronger Patent Protection in India Might Affect the Behavior of Transnational Pharmaceutical Industries." World Bank Policy Research Working Paper No. 2352.
14. Gandhi, Indira (1988). "Address Before the World Health Assembly." In Intellectual Property Rights: Global Consensus, Global Conflict, edited by R. M. Gadbaw and T. Richards. Westview Press.
15. Grossman, Gene, and Edwin Lai (2004). "International Protection of Intellectual Property." American Economic Review, 94, 1635-1653.
16. Helpman, Elhanan (1993). "Innovation, Imitation, and Intellectual Property Rights." Econo- metrica, 61, 1247-1280.
17. ICRA (1999). The Indian Pharmaceutical Industry. ICRA Industry Watch Series.
18. Kyle, Margaret K. (2007). "Pharmaceutical Price Controls and Entry Strategies." Review of Economics and Statistics, 89, 88-99.
19. Lanjouw, Jean O. (1998). "The Introduction of Pharmaceutical Product Patents in India: Heart- less Exploitation of the Poor and Suffering?" National Bureau of Economic Research Working Paper No. 6366.
20. Lanjouw, Jean O. (2005). "Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry. " National Bureau of Economic Research Working Paper No. 11321.
21. Lanjouw, Jean O., and Iain Cockburn (2001). "New Pills for Poor People? Empirical Evidence after GATT." World Development, 29, 265-289.
22. Lu, John L., and William S. Comanor (1998). "Strategic Pricing of New Pharmaceuticals." Review of Economics and Statistics, 80, 108-118.
23. Maskus, Keith E., and D. Eby Konan (1994). "Trade-related Intellectual Property Rights: Issues andExploratoryResults. "In AnalyticalandNegotiatingIssuesintheGlobalTradingSystem, edited by A. V. Deardoff and R. M. Stern. University of Michigan Press.
24. Narayana, P. L. (1984). The Indian Pharmaceutical Industry: Problems and Prospects. NCAER.
25. Nogues, Julio J. (1993). "Social Costs and Benefits of Introducing Patent Protection for Pharmaceutical Drugs in Developing Countries." The Developing Economies, 31, 24-53.
26. Nordhaus, William (1969). Invention, Growth and Welfare: A Theoretical Treatment of Technological Change. MIT Press.
27. Oxford Analytica (2006). "INDIA: Price Controls Pose Risk to Drug Industry." 23 October.
28. Redwood, Heinz (1994). New Horizons in India: The Consequences of Pharmaceutical Patent Protection. Oldwicks Press.
29. Subramanian, Arvind (1995). "Putting Some Numbers on the TRIPS Pharmaceutical Debate." International Journal of Technology Management, 10, 252-268.
30. Vickers, John (2009). "Competition Policy and Property Rights." University of Oxford, Department of Economics Discussion Paper Series, No. 436.
31. Watal, Jayashree (2000). "Pharmaceutical Patents, Prices and Welfare Losses: A Simulation Study of Policy Options for India under the WTO TRIPS Agreement." World Economy, 23, 733-752.
32. World Health Organization (2002). World Health Report. WHO.